LLY
Eli Lilly and Company
LLY has the edge over RXST overall, supported by stronger fundamentals and lower modeled downside.
RXST
RxSight, Inc.
RXST's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RXST Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
RXST's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RXST PE Valuation
RXST has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RXST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RXST's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RXST on earnings quality, reporting a profit while its opponent remains loss making.
RXST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.41 |
| Q2 2026 | -$1.13 | -$0.34 |
| Q1 2026 | -$1.13 | -$0.47 |
| Q4 2025 | -$0.95 | -$0.24 |
| Q3 2025 | -$0.87 | -$0.06 |
| Q2 2025 | -$0.79 | +$0.21 |
| Q1 2025 | -$0.66 | +$0.58 |
| Q4 2024 | -$0.71 | +$0.70 |
RXST is still losing money, but far less than before: $1.28 per share over the past year, against $3.19 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RXST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RXST on profitability, with a higher operating margin.
RXST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.6M | -19% |
| Q2 2026 | $33.7M | +0.3% |
| Q1 2026 | $30.9M | -18% |
| Q4 2025 | $32.6M | -19% |
| Q3 2025 | $30.3M | -14% |
| Q2 2025 | $33.6M | -3.6% |
| Q1 2025 | $37.9M | +28% |
| Q4 2024 | $40.2M | +41% |
RXST's revenue has slid since its 2024 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | -35 points |
| Q2 2026 | -41% | +0.8 points |
| Q1 2026 | -58% | -30 points |
| Q4 2025 | -35% | -13 points |
| Q3 2025 | -40% | -14 points |
| Q2 2025 | -42% | -18 points |
| Q1 2025 | -28% | +8 points |
| Q4 2024 | -21% | +17 points |
RXST's operating margin was −75% last quarter, down 35 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RXST on cash flow, with more consistent year-over-year improvement.
RXST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44M | +$45.8M |
| Q2 2026 | -$11.5M | -$5.6M |
| Q1 2026 | -$11.7M | -$2.2M |
| Q4 2025 | -$2.3M | +$2.9M |
| Q3 2025 | -$1.8M | -$1.3M |
| Q2 2025 | -$5.9M | -$363K |
| Q1 2025 | -$9.4M | +$1.9M |
| Q4 2024 | -$5.1M | +$4.8M |
RXST's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RXST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RXST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +215K shares |
| 1 year | +1.8% | +740K shares |
| 3 years | +17% | +6M shares |
| 5 years | +901% | +37.5M shares |
| Available history | +119% | +22.6M shares |
RXST has 42M diluted shares, up 1.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RXST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 0.3x | Very low |
| Q4 2020 | 0.5x | Very low |
RXST's net debt is less than a year of its operating earnings (EBITDA).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RXST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 22.2 | Neutral |
RXST's weekly RSI is 47 (neutral) and its Stochastic is 22 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RXST PE vs Healthcare Sector
RXST has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RXST on trend strength, trading above more of its moving averages.
RXST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.81 | 12% above |
| 20 week MA | $5.49 | 2% below |
| 50 week MA | $6.88 | 22% below |
| 100 week MA | $11.9 | 55% below |
| 200 week MA | $24.9 | 78% below |
RXST has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 78% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RXST on returns for 2026, with the stronger performance.
RXST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.0 | $10.6 | -34% |
| 2022 | $10.6 | $11.9 | +12% |
| 2023 | $11.9 | $40.3 | +239% |
| 2024 | $40.3 | $34.2 | -15% |
| 2025 | $34.2 | $10.9 | -68% |
| 2026 YTD | $10.9 | $5.38 | -51% |
RXST's yearly returns have swung widely, from +239% in 2023 to −68% in 2025. It's down 51% so far in 2026.